Mesenchymal Stem Cells to Repair Vascular Damage after Chemotherapy: Past, Present and Future

Similar documents
Mesenchymal Stem Cells

Journal Club WS 2012/13 Stefanie Nickl

Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy

Cell implantation after myocardial infarction: a 10 years experience from the ICREC laboratory

Strategic Research Development in Stem Cell and Regenerative Medicine in HKU Professor Sum-ping Lee Dean HKU Li Ka Shing Faculty of Medicine

Stem Cell Therapy Concept. Pleuripotent Stromal Cells 8/8/2011. Use of Adipose-Derived Stem Cells in Regenerative Therapy

Use of Adipose-Derived Stem Cells in Regenerative Therapy. David Euhus, MD Professor of Surgery UT Southwestern Medical Center at Dallas

Dr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK

Review. Mesenchymal Stem Cells: Biology, Pathophysiology, Translational Findings, and Therapeutic Implications for Cardiac Disease

DOWNLOAD PDF CARDIAC REMODELING AND CELL DEATH IN HEART FAILURE

ENDOGENOUS CARDIAC STEM CELLS IN THE REGENERATION OF ACUTE AND CHRONIC ISCHEMIC MYOCARDIUM

Multimodality Imaging in Cardiac Stem Cell Research

Tissue renewal and Repair. Nisamanee Charoenchon, PhD Department of Pathobiology, Faculty of Science

CD90 + Human Dermal Stromal Cells Are Potent Inducers of FoxP3 + Regulatory T Cells

Stem Cells and Sport Medicine

Stem Cells. Keith Channon. Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford

Pathophysiology. Tutorial 3 Hemodynamic Disorders

Protocol. Progenitor Cell Therapy for the Treatment of Damaged Myocardium due to Ischemia

VWF other roles than hemostasis. Summary 1: VWF & hemostasis synthesis 11/4/16. Structure/function relationship & functions kDa.

Stem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT

Professor Harvey White. Interventional Cardiologist Auckland

In Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison

Supplementary material page 1/10

Citation for published version (APA): Velde, S. V. D. (2006). Stem cell-mediated regeneration of the infarcted heart: inflammation rules? s.n.

stem cell products Basement Membrane Matrix Products Rat Mesenchymal Stem Cell Growth and Differentiation Products

Ricardo E. Colberg, MD, RMSK. PM&R Sports Medicine Physician Andrews Sports Medicine and Orthopedic Center American Sports Medicine Institute

Bone Cell Precursors and the Pathophysiology of Bone Loss

STEM CELLS. Dr Mohammad Ashfaq Konchwalla Consultant Orthopaedic Sports Surgeon

Tissue repair. (3&4 of 4)

Cardiovascular Stem Cell Therapy

CorMatrix ECM Bioscaffold

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

SUPPLEMENTAL MATERIAL

Medical Coverage Policy Progenitor Cell Therapy for the Treatment of Damaged Myocardium due to Ischemia

Cell Therapy Update what have we learned from clinical trials?

Ischemic heart disease

WIEF-AFF ROUNDTABLE Tokyo, Japan 26 May 2015

Structural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak

Regenerative Medicine for Cardiomyocytes

European Society of Cardiology Congress DONOR AGE NEGATIVELY INFLUENCES THE CYTOPROTECTIVE PARACRINE EFFECTS EXERTED BY HUMAN MESENCHYMAL STEM CELLS

NIH Public Access Author Manuscript Regen Med. Author manuscript; available in PMC 2013 March 21.

Signaling Vascular Morphogenesis and Maintenance

Progenitor Cell Therapy for the Treatment of Damaged Myocardium due to Ischemia. Original Policy Date

TRANSLATIONAL AND CLINICAL RESEARCH

Journal Club Semmler Lorenz

Chapter 6. Villous Growth

DISCOVERING ATCC IMMUNOLOGICAL CELLS - MODEL SYSTEMS TO STUDY THE IMMUNE AND CARDIOVASCULAR SYSTEMS

Cell Combination Therapy. Disclosures

EARLY INFLAMMATORY RESPONSES TO VASCULAR DEVICES

Stem cell therapy aimed at restoring organ function,

Mesenchymal Stem Cells and Cancer: Their Interplay

Vice Dean and Professor of Medicine

Hemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.

Resident cardiac stem cells: how to find and use them

CD34+ Cells: A Comparison of Stem and Progenitor Cells in Cord Blood, Peripheral Blood, and the Bone Marrow

Choosing Study Outcomes that Reflect Cardiovascular Disease: From Biomarkers to Burden of Disease. Greg Wellenius Joel Kaufman

Irreversible shock can defined as last phase of shock where despite correcting the initial insult leading to shock and restoring circulation there is

Disturbance of Circulation Hemodynamic Disorder

Uncovering the mechanisms of wound healing and fibrosis

Zachary I. Hodes, M.D., Ph.D., F.A.C.C.

renoprotection therapy goals 208, 209

Cell-based therapy for prevention and reversal of myocardial remodeling

Stem Cell Therapy in AMI

Pathology of Coronary Artery Disease

DECLARATION OF CONFLICT OF INTEREST. No conflicts of interest

No option-patients : Is angiogenesis with gene or cell therapy still an option?

What s a Transplant? What s not?

Regulatory role of mesenchymal stem cells in osteoclast differentiation. , Masahiro Kondo and Yoshiya Tanaka 1, )

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Small Platform Catheter-Based Left Ventricular Assist Device Support Suppresses Cardioprotective Beta Arrestin- Mediated Signal Transduction

Supplementary Table S1: Proportion of missing values presents in the original dataset

Pathology of Cardiovascular Interventions. Body and Disease 2011

E. Cervio, P. Danieli, C. Ciuffreda, F. Pisano, M. Roccio, M. Gnecchi. The authors have no financial disclosures to declare

Imaging of Coronary Artery Disease: II

Novel Concept Regenerative, Immune-Privileged, Bio-Stentgraft

Accelerate Your Research with Conversant Bio

Devices are So Old School: The New World of Myocardial Regeneration

3/27/2014. Introduction.

Diabetic eye disease. Diabetic retinopathy. Sam S. Dahr, M.D. Retina Center of Oklahoma.

Future of stem cell therapy in liver disease Domenico ALVARO, MD Sapienza, University of Rome, Italy

Cytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,

Blood. Hematopoietic Tissue

BEDSIDE ASSESSMENT OF PATIENTS WITH STEMI

Most cells in the human body have an assigned purpose. They are liver cells, fat cells, bone cells,

Chapter 12 Cardiovascular System

Myocardial Infarction

Bone marrow stroma: biology and therapeutic exploitation

What are stem cells? A stem cell can differentiate into any one of 220 different specialised cells in the body STEM CELLS

Hematopoiesis. BHS Liège 27/1/2012. Dr Sonet Anne UCL Mont-Godinne

9/23/2017. Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota

WOUND CARE UPDATE. -Commonly Used Skin Substitute Products For Wound. -Total Contact Casting. Jack W. Hutter DPM, FACFAS, C. ped.

Common Codes for ICD-10

SUPPLEMENTARY INFORMATION

EACTS Adult Cardiac Database

Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Blood and Marrow Transplant (BMT) for Sickle Cell Disease

Bone Marrow Stroma in Myelodysplastic Syndromes

Introducing the COAPT Trial

Stem cells for cardiac repair

Transcription:

Mesenchymal Stem Cells to Repair Vascular Damage after Chemotherapy: Past, Present and Future Cell Therapy 2014 Las Vegas, NV, USA Sulaiman Al-Hashmi, PhD Sultan Qaboos University Oman

What are MSCs? Stem cell capacity Stromal property Non-hematopoietic cells Multipotent cells 0.001-0.01% of nucleated cells in BM Adhere to culture plate Express variable range of cell markers

Totipotent Pluripotent Multipotent http://www.york.ac.uk/res/bonefromblood/background/osteogenesis.html

MSCs Self renewal Muscle cells Neurocytes Adipocytes (Fat) Chondrocytes (Cartilage) Osteoblast (Bone)

Bone marrow MSC Sources Peripheral blood Cord blood Placenta and fetal membrane Adipose tissue Hass et al 2011; Orbay et al 2012

Common MSC Markers Negative Markers CD34 CD45 CD11b and CD14 CD79α & CD19α HLA Class II Positive Markers CD73/5 -Nucleotidase CD90/Thy1 CD105/Endoglin Roles Primitive hematopoietic cells and endothelial cells Leukocytes Monocytes and macrophages B cells Antigen presenting cells and lymphocytes Catalyzes production of extracellular adenosine from AMP Wound repair, cell-cell and cell-matrix interactions Vascular homeostasis; modulates TGF-β functions via interaction with TGF-β receptors (RI & RII) Dominici et al 2006

MSC Clinical Applications Hematopoietic Stem Cell Transplantation Enhance engraftment Reduce graft versus host disease Solid Organ Transplantation Improved graft function Reduced rejection Repair Vascular Damage Chemotherapy Radiotherapy Others

Chemotherapy and Vascular Toxicity Edward et al 2004

Bu-Cy and Vascular Toxicity Al-Hashmi et al, 2012

Bu-Cy and Vascular Toxicity Control Unbroken endothelial cell-cell contact uniform endothelial surface Bu-Cy Detaching of endothelial cells Cell-cell contacts were disrupted rounded and frequently blebs 11/1/2014 Al-Hashmi et al, 2012

Chemotherapy & Vascular Toxicity Cisplatin-based therapy Testicular cancer patients Before and after chemotherapy MI, myocardial infarction; DVT, deep vein thrombosis; PE, pulmonary embolism; vwf, von Willebrand factor Nuver et al, 2005

MSC Source Rat BM Injury induction Ligation of proximal left coronary artery MI MSC infusion MSCs and Vascular Repair Infarct area (2 x 10 6 ) Outcomes Expressed muscle and endothelium markers Improved LV function Dai et al 2005

MSCs and Vascular Repair MSC Source Canine BM Injury induction Ameroid constrictor placement Chronic myocardial ischemia MSC infusion Intramyocardial injections (10 x 10 7 ) Outcomes Improved ejection fraction & vascular density Increased vascularity Improved cardiac function MSC Differentiation SMCs & ECs Silva et al 2005

MSCs and Vascular Repair MSC Source Porcine BM Injury induction Occlusion followed by reperfusion of the anterior coronary artery MI MSC infusion Intramyocardial injections (20 x 10 7 ) Outcomes Improved myocardial blood flow Improved ventricular & late cardiac functions Enhanced blood vessels maturation Reduced endomyocardial apoptosis Reduced infarct scarring Schuleri et al 2008

MSCs and Vascular Repair MSC Source Porcine BM Injury induction Carotid artery cannulation MI MSC infusion Transendocardial injections (10 x 10 7 ) Outcomes Differentiated into cardiomyocytes and vascular structures Stimulated endogenous cardiac stem cells proliferation and differentiation Stimulated cardiomyocyte replication Reduced infarct size Hatzistergos et al 2010

MSCs and Vascular Repair MSC Source C57Bl/6 mice BM Express GSK-3 Injury induction Carotid artery ligation MI MSC infusion Border zone of MI (1.5x 10 5 ) Outcomes GSK-3 increased MSCs survival GSK-3 -MSCs induced cardiomyocyte differentiation and angiogenesis GSK-3 MSCs increased capillary density GSK-3 MSCs upregulated paracrine factors (VEGF-A) Cho et al 2011

Cho et al 2011

MSCs and Vascular Repair MSC Source C57Bl/6 mice BM Injury induction Removal of endothelium with a flexible wire Carotid artery injury MSC infusion IV injection (1 x 10 5 ) Outcomes Differentiated into neo-ecs in the injury Contributed to vascular remodeling Expressed different markers Formed the tube-like structure Li et al 2013

Li et al 2013

MSCs in clinical practice (Meta Analysis) Searched databases PubMed, OVID, EMBASE, the Cochrane Library, and ClinicalTrials.gov Outcome Improved LVEF in patients Efficacy of Cells in transplantation influenced by Source of cells Route of infusion Type of injury BMCs & MSCs infusion is a safe and effective therapy to improve vascular repair Xiao et al 2014; Xu et al 2014; Tian et al 2014

Precautions Intra-myocardial calcification Vascular calcification Increase aortic stiffness Systolic hypertension Transient improvement Unregulated differentiation Liao et al 2012; Dai et al 2005

Prospective MSC therapy under intensive investigation Establish clinical relevant vascular injury models Sources & doses Timing Protocols Collaboration Type of disease Data sharing

Liao et al 2012

MSCs in clinical practice Elnakish et al 2012

Cancer Gene Therapy (2014), 12 23